SMS Pharmaceuticals — 360° view

SMS Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹316 crore and net profit of ₹40 crore for the September 2026 quarter.

SMS Pharmaceuticals (NSE: SMSPHARMA) closed at ₹473.25 on 20 Nov 2026, up 66.7% over the past year. Its market capitalisation is ₹4,432 crore and it trades at 37.9 times earnings.

Share price
₹473.25 (20 Nov 2026)
Market cap
₹4,432 Cr (20 Nov 2026)
P/E
37.90 (20 Nov 2026)
Revenue
₹316 Cr (September 2026 quarter)
Net profit
₹40 Cr (September 2026 quarter)
ROCE
13.3% (FY26)
ROE
14.3% (FY26)
Book value
₹90.0 (FY26)
Dividend yield
0.17% (last 12 months to 20 Nov 2026)
52-week high / low
₹535.00 / ₹270.10 (20 Nov 2026)
1-year return
66.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SMSPHARMA

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.